|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [3. pielikums](http://www.likumi.lv/wwwraksti/2016/034/104/P3.DOCX%22%20%5Co%20%22Atv%C4%93rt%20cit%C4%81%20form%C4%81t%C4%81)Ministru kabineta2016. gada 16. februāranoteikumiem Nr. 104**Epidemioloģiski nozīmīgu baktēriju uzskaites veidlapa stacionārās ārstniecības iestādēs**

|  |  |
| --- | --- |
| Iestādes nosaukums |   |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Kods |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

|  |  |  |  |
| --- | --- | --- | --- |
| Pārskata periods |   |   |   |
|   | (gads) |   | (ceturksnis) |
|   | Kopējais pacientu skaits ar pirmreizēji izdalītu baktēriju | t. sk.intensīvās terapijas nodaļās\* | t. sk.slimo jaundzimušo nodaļās\* | t. sk.paraugs ņemts skrīninga\*\*izmeklējumam |
| Pret meticilīnu rezistents*Staphylococcusaureus* (MRSA) |   |   |   |   |
| Pret vankomicīnu rezistents*Staphylococcus aureus* (VRSA) |   |   |   |   |
| Pret vankomicīnu rezistents *Enterococcus*(VRE) |   |   |   |   |
| *Clostridium difficile* |   |   |   |   |
| Pret karbapenēmiem rezistents*Acinetobacter spp./Acinetobacter baumannii* |   |   |   |   |
| Plaša spektra beta-laktamāzi*(ESBL*), t. sk. karbapenemāzi, producējošas gramnegatīvas nūjiņas |   |   |   |   |
| Citas\_\_\_\_\_\_\_\_\_ |   |   |   |   |
| Kopā |   |   |   |   |

Piezīmes.1. \* Pirmais pozitīvais paraugs.2. \*\* Augsta riska grupas pacientu izmeklēšana.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   |   |   |   |   |
| (amats) |   | (vārds, uzvārds) |   | (tālruņa numurs) |

|  |  |  |
| --- | --- | --- |
| 20\_\_. gada.\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |   | Paraksts \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

 |   |